Canada markets closed

Atossa Therapeutics, Inc. (ATOS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8123-0.0265 (-3.16%)
At close: 04:00PM EST
0.8380 +0.03 (+3.16%)
After hours: 07:58PM EST
Full screen
Loading interactive chart...
  • GlobeNewswire

    Atossa Therapeutics Issues Letter to Shareholders

    SEATTLE, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet need in cancer, today announces the issuance of the following Letter to Shareholders from Steven C. Quay, M.D., Ph.D., the Company’s CEO and Chairman: TO OUR VALUED STOCKHOLDERS: 2022 was a year of significant progress for Atossa. We focused our development efforts on advancing our breast cancer pr

  • GlobeNewswire

    Atossa Therapeutics Announces the Appointment of Eric Van Zanten as Vice President, Investor and Public Relations

    SEATTLE, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology, is pleased to announce the appointment of Eric Van Zanten as Vice President of Investor and Public Relations. Mr. Van Zanten brings over 25 years of corporate communications experience working within the biopharmaceutical, finance, and healthcare industries. He will oversee corporate

  • GlobeNewswire

    Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

    SEATTLE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), today announces financial results for the fiscal quarter ended September 30, 2022, and provides an update on recent company developments. Atossa is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments. Key developments from Q3 2022 and to date incl